AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
Titel:
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
Auteur:
Black, Mark D. Stevens, Rachel J. Rogacki, Nancy Featherstone, Robert E. Senyah, Yaw Giardino, Odessa Borowsky, Beth Stemmelin, Jeanne Cohen, Caroline Pichat, Philippe Arad, Michal Barak, Segev Levie, Amaya De Weiner, Ina Griebel, Guy Varty, Geoffrey B.